The present invention relates to an improved process for the preparation of Silodosin (I) which is useful in the treatment of Benign Prostate Hyperplasia (BPH) and related disorders. The present invention also relates to the purification process resulting in substantially pure Silodosin.

ABSTRACT The present invention relates to a process for the preparation of crystalline Form G of tenofovir alafenamide hemifumarate .The invention further relates to pharmaceutical compositions comprising crystalline Form G of tenofovir alafenamide hemifumarate, useful in the treatment treat or prevent diseases o...

The present invention relates to improved process for the preparation of highly pure Pirfenidone (I). Formula I Pirfenidone (I) is an anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF).

Improved processes for the preparation of Rifaximin. Particularly, improved processes for the preparation of Rifaximin from Rifamycin O and S. More particularly a novel polymorph of Rifaximin and process for its preparation are provided.

ABSTRACT The present invention relates to novel crystalline Form G of Dimethyl Fumarate having the following Formula I Formula I

The present invention relates to process for the preparation of Darunavir or a solvate thereof of Formula I using a novel intermediate (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (2S,3R)-4-(4-(1,3-dioxoisoindolin-2-yl)-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate Compound of formula (II): ...

Abstract A continuous or batch process for the preparation of primary and secondary N-acetylated aromatic amines or O-acetylated product of hydroxy benzoic acids The present invention relates to continuous processes for the preparation of primary and secondary N-acetylated aromatic amines of formula I or O-acetylat...

The present invention relates to a process for the preparation of amino alcohol derivatives or salts thereof. In particular the present invention relates to process for the preparation of amino alcohol derivatives or salts thereof which may be used as intermediates in the preparation of HIV reverse transcriptase inh...

The present invention relates to a process for the preparation of crystalline Form Gl of Ertugliflozin (I). The invention also relates to crystalline Form Gl obtained by the process of the present invention, the said Form Gl being substantially pure, stable, and characterized by X-ray powder-diffraction pattern ...

The present invention relates to improved process for the preparation of Temozolomide Formula I. (I) Said Temozolomide (I) is useful in the treatment of cancer.

The present invention relates to an improved process for the preparation of nucleoside derivative which are used as agents in the treatment of viral diseases. In particular, the present invention relates to process for the preparation of a nucleotide analog inhibitor of HCV NS5B polymerase.

ABSTRACT The present invention relates to an improved process for the preparation of compounds of formula I This intermediate is chemically designated as (E)-2-halo-3-(dimethylamino)acrylaldehyde. The compound of Formula I is a key useful intermediate in the preparation Etoricoxib.

The present invention relates to one pot process for the preparation of acetylated amino phenols from aryl nitro compounds.

ABSTRACT The present invention relates to stable amorphous form of a HIV protease inhibitor, namely, Atazanavir. The present invention preferably relates to stable amorphous form of Atazanavir free base. The present invention also relates to an improved process for the preparation of Atazanavir sulfate from amorpho...

ABSTRACT The present invention relates to an improved process for the preparation of DPP-IV inhibitors. In particular, the present invention relates to an improved process for the preparation of Teneligliptin. More particularly, the present invention relates to an improved process for the preparation of Teneliglipt...

The present invention relates to improved process for the preparation of gliclazide of formula I. (I) Gliclazide (I) is useful in the treatment of diabetic.

The present invention relates to a stable amorphous form Teneligliptin oxalate (I). (I) The invention also relates to stable amorphous form obtained by the process of the present invention, the said amorphous form being substantially pure. Said amorphous form is useful in preparing pharmaceutical compositi...

ABSTRACT The present invention relates to a commercially viable process for the preparation of Eltrombopag Olamine of formula (I) I II using novel commercially useful eltrombopag amine salts of formula (II). Eltrombopag Olamine of formula (I) is useful as a thrombopoietin (TPO) receptor agonist indicat...

The present invention relates to improved process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol (I). (I) (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol (I) is useful as intermediate in the preparation of of anti-retroviral drugs.

The present invention relates to an improved and industrially advantageous process for the preparation of Rifaximin with high purity and yield. Particularly the present invention relates to improved processes for the preparation of Rifaximin from Rifamycin O and S. More particularly the present invention relates to ...

NOVEL POLYMORPHIC FORMS OF ((1S,2S,3S,4R,5S))-2,3,4-(TRIS-BENZYLOXY)-5-(4-CHLORO-3-(4-ETHOXY-BENZYL)PHENYL)-6,8-DIOXA-BICYCLO[3.2.1]OCT-1-YL-METHANOL ABSTRACT The present invention relates to novel polymorphs of ((1S,2S,3S,4R,5S))-2,3,4-(tris-benzyloxy)-5-(4-chloro-3-(4-ethoxy-benzyl)phenyl)-6,8-dioxa-bicyclo[3.2....

The present invention relates to an improved process for the preparation Crystalline Form G2 of Rifaximin of Formula (I).  (I) The invention also relates to crystalline Form G2 of Rifaximin (I) obtained by the process of the present invention, the said Form G2 being substantially pure, stable and characterize...

The present invention relates to a process for the preparation of Teneligliptin oxalate The invention also relates to stable crystalline form designated as form Gl obtained by the process of the present invention, the said crystalline form being substantially pure. Said crystalline form is useful in preparing phar...

PIMAVANSERIN PROCESS ABSTRACT The present invention relates to process for the preparation of Pimavanserin of formula (I) using a novel intermediate 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl) -1-(1-methylpiperidin-4-yl)thiourea (II). (I) (II) Pimavanserin (I) is useful in the treatment of Parkinson’...

The present invention relates to improved process for the preparation of Pimavanserin of formula (I) (I) Pimavanserin (I) is useful in the treatment of Parkinson’s disease psychosis.

The present invention relates to improved process for the preparation of Guaifenesin Formula I using Heat transfer fluids. (I)

The present invention relates to a process for the preparation of N-(4-fluorobenzyl)- N-(1- methylpiperidin-4-yl)-N’-(4-(2-methylpropyloxy)-phenylmethy)carbamide or Pimavanserin of Formula (I). (I) The present invention further relates to process for the purification of N-(4-fluorobenzyl)- N-(1- methylpiperidi...

The present invention relates to improved and commercially viable process for the preparation of Trientine dihydrochloride of formula I. (I) Trientine dihydrochloride (I) is a therapeutically useful chelating agent which is used to bind and remove excess copper in the body in order to treat Wilson"s disease,...

The present invention relates to pharmaceutical composition comprising crystalline Rifaximin, Poloxamer, Stearyl polyoxyl-32 glyceride and one or more pharmaceutically acceptable excipient(s) where in Rifaximin has average particle diameter ranging between 10-100 microns, and crystalline forms are selected from Form...

The present invention relates to a process for the preparation of crystalline Form GR of Rifaximin (I). (I) The invention also relates to crystalline Form GR of Rifaximin obtained by the process of the present invention, the said Form GR being substantially pure, stable, and characterized by X-ray powder di...

A PROCESS FOR THE PARTICLE SIZE REDUCTION ABSTRACT Particular aspects of the present invention relates to a process for the prcpmr~tion of pirfcnidonc (I) having partic.lc size < 2001Jm comprising the steps of: o-N;)H" 0 Formula I a. providing a solution of Pirfenidonc in an organic solvent at temperature ...

PROCESS FOR THE PREPARATION OF D- PENICILLAMINE ABSTRACT The present invention relates to improved process for the preparation of D-Penicillamine of formula I. (I) D-Penicillamine (I) and salts thereof are well known to be useful in the treatment of Wilson’s disease, rheumatoid disease and cystinuria. ...

The present invention relates to continuous drying process for metformin, acetaminophen or their granulate composition/s by Spin Flash Drying process to manufacture pharmaceutical grade material on larger scale safer operations.

The present invention relates to commercially viable process for the preparation of Cabozantinib of formula (I) and its pharmaceutically acceptable salts for the treatment of patients with advanced renal cell carcinoma (RCC) and for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC...

ABSTRACT The present invention relates to an improved process for the preparation of Lenvatinib of formula (I) which is useful in the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. (I) The present invention also relates ...

PHARMACETICAL COMPOSITIONS OF IBUPROFEN AND FAMOTIDINE ABSTRACT The present invention relates to stable pharmaceutical compositions of Ibuprofen and Famotidine in a single unit dosage form. The present invention also provides trilayer tablet and tablet-in-tablet dosage forms comprising Ibuprofen and Famotidine. It...

The present invention relates to the field of Pharmaceuticals, more particularly, the invention relates to an improved process for the synthesis of Vasopressin, chemically represented by the formula (1).

The present invention relates to stable pharmaceutical compositions of Guaifenesin comprising microspheres of Guaifenesin compressed into oral dosage forms comprising two portions of guaifenesin in the form of immediate release portion and extended release portion. The present invention also relates to Guaifenesin m...

The present invention relates to an improved, industrially applicable and commercial scalable crystallization process to yield a highly pure product of Guaifenesin (Formula I) with controlled particle size distribution and an improved purity profile, wherein the process involves the use of heat liberation while crys...

This invention is directed to a method for synthesis and purification of Losartan of the formula (I), its intermediates and pharmaceutically acceptable salts and solvents thereof; also herein described are the compositions comprising substantially pure Losartan free base or salts thereof free of the well-known ...

The present invention relates to a commercially viable improved process for the preparation of Prazosin hydrochloride of formula (I) for the treatment of patients with hypertension to reduce the blood pressure as reducing the blood pressure lowers the risk of fatal and nonfatal cardiovascular events, primarily stoke...

The present invention relates to Pharmaceutical composition of Ibuprofen or its pharmaceutically acceptable salt, enantiomers thereof, wherein said composition comprising 75 to 90 % by weight of Ibuprofen; 0.05% to 0.2% by weight of Sodium lauryl sulfate; 2% to 5% by weight of binder; 3% to 6% by weight of a disinte...

The present invention relates to improved pharmaceutical compositions of Pirfenidone comprising Pirfenidone and one or more pharmaceutically acceptable excipients, wherein the said composition is free of binding agent. The present invention also relates to process for preparing pharmaceutical composition of Pirfenid...

ABSTRACT The present invention relates to an improved and commercially viable process for the preparation of Lapatinib (I) and its salts, wherein the impurities in particular the isomeric impurities of compound of Formula IIIa and Formula IIIb are controlled and found to be absent, or below the level of detection ...

The present invention relates to the field of Pharmaceuticals and chemistry; more particularly, the invention relates to an improved process for synthesis of a commercially scalable, solid powder form of Levocetirizine and Cetirizine base which is chemically represented by the formula I and II respectively. 2-[...

AN IMPROVED PROCESS FOR THE PREPARATION OF SARTAN, FREE OF GENOTOXIC AZIDE IMPURITIES The present invention relates to the synthesis and purification of Losartan of the Formula (I), its intermediates and pharmaceutically acceptable salts and solvates thereof; also herein described are precise reaction conditio...

CONTINUOUS METHOD FOR MANUFACTURING P-AMINO PHENOL AND DERIVATIVES THEREOF The present invention relates to a continuous process for the preparation and purification of p-Aminophenol (PAP) from nitrobenzene by use of catalytic hydrogenation wherein a loop Venturi reactor is employed, which results in creating ...

AN IMPROVED PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN, FREE OF ACID AND FURANOSE IMPURITIES The present invention is to provide an improved process for the synthesis of amorphous Dapagliflozin of formula I through Dapagliflozin (S/RS)-1,2-propanediol, wherein the process yields substantially pure product fr...

AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED BI-PHENYL CARBOXYLIC ACID COMPOUND AND IT’S USE IN THE PREPARATION OF ELTROMBOPAG ABSTRACT The present invention relates to an improved process for the preparation of Substituted Bi-Phenyl Carboxylic Acid Compound. More specifically it relates to a process f...

AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB ABSTRACT The main objective of the present invention is to improve the process for the preparation of ruxolitinib using protected (E)-N-(3-(Dimethylamino)-2-(7H-pyrrolo[2,3-d] pyrimidin-4-yl) allylidene)-N-methylmethanaminium chloride hydrochloride and (R)-...

AN IMPROVED PROCESS FOR THE PREPARATION OF EMPAGLIFLOZIN, FREE OF ACID AND FURANOSE IMPURITIES The present invention is to provide an improved process for the synthesis of Empagliflozin, wherein the process yields substantially pure product free of the acid and furanose impurities, further which involve singl...

ABSTRACT “NOVEL CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE SALTS” The present invention relates to novel crystalline forms of tenofovir alafenamide salts and process for the preparation thereof. More, particularly the present invention relates to novel crystalline form of tenofovir alafenamide hemi maleate, ...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF VILOXAZINE HYDROCHLORIDE: The present invention relates to an improved process for the preparation of Viloxazine hydrochloride of formula I with high yield and purity. Formula I Dated this: 28th day of March, 2024. ...

ABSTRACT METHOD OF MANUFACTURING OF DICYANDIAMIDE: The present invention generally relates to a method of manufacture of Dicyandiamide (popularly known in industry as DCDA), and in particular it relates to an energy efficient, two step, green method of manufacture of Dicyandiamide. Dated this 16th day of May,...

ABSTRACT IMMOBILISED WHOLE CELL NITRILASES FOR BIOCATALYSIS OF GABAPENTIN INTERMEDIATE: The present invention relates to immobilization of whole cell having nitrilase activity by cross-linked cell aggregates (CLCAs) and the use of such immobilized whole cell nitrilase enzymes for nitrile biocatalysis of gabapent...

ABSTRACT IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB AND NOVEL CRYSTALLINE FORM THEREOF: The present invention relates to an improved process for the preparation of ruxolitinib or its salts and intermediates thereof. The present invention also relates to a novel crystalline form G of ruxolitinib, a process...

ABSTRACT ONE-POT PROCESS FOR THE PREPARATION OF GABAPENTIN INTERMEDIATE The present invention provides a one-pot process for the preparation of 1-(cyanomethyl) cyclohexane-1-carbonitrile, which is a key intermediate for preparation of gabapentin. Particularly, the present invention provides a one-pot process f...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF 5-BROMO-4-(4- CHLOROTHIOPHEN-2-YL)THIAZOL-2-AMINE, SUBSTANTIALLY FREE OF DIBROMO IMPURITY AND NOVEL POLYMORPHIC FORMS OF AVATROMBOPAG FREE BASE & IT’S INTERMEDIATE The present invention relates to an improved process for the preparation of 5-bromo-4-(4-chloroth...

ABSTRACT IMPROVED PROCESS FOR THE PREPARATION OF AMPHETAMINE AND DERIVATIVES THEREOF: The present invention relates to an improved process for the preparation of amphetamine and it’s derivatives thereof, using a silane reagent as a hydrogen source, which is economical, green and safe method with simple operation, ...

NOVEL PROCESS FOR THE PREPARATION OF ELACESTRANT AND ITS INTERMEDIATES THEREOF The present invention relates a novel process for the preparation of elacestrant of formula I or a salt thereof. The present invention particularly relates a novel intermediate compounds, process for the preparation and its use in t...

NOVEL PROCESS FOR THE PREPARATION OF ELACESTRANT AND ITS INTERMEDIATES THEREOF The present invention relates a novel process for the preparation of elacestrant of formula I or a salt thereof. The present invention particularly relates a novel intermediate compounds, process for the preparation and its use in t...

The present invention relates to an improved process for the preparation of Daprodustat. Specifically, the invention provides a simple, cost-effective, commercially viable, and industrially applicable method for synthesizing Daprodustat of formula I. Formula I